Lebrikizumab Therapeutic Cheat Sheet
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. …
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. … 
Topical and systemic medications are mainstays of acne treatment, targeting excess oil, clogged pores, bacteria, and inflammation. An original article published in the June Journal of Drugs in Dermatology calls for research on an adjunct acne treatment modality that addresses an unusual target: psychological stress. The authors contend psychological stress can influence acne, and psychotherapeutic … 
Slate recently published a first-person account of fibrosing alopecia in a pattern direction (FAPD) in the article, “I’m 25, and I Have a Cosmetic Problem That No One Wants – and That’s Maddening to Fix.” The article details the writer’s years-long experience with hair thinning, and how it took until an irregular blood test and scalp biopsy for an FAPD diagnosis. The writer’s treatme … 
Recent advances in photodermatology have expanded our understanding of how multiple wavelengths across the electromagnetic spectrum contribute to skin damage, aging, pigmentary disorders, and skin cancer risk. While ultraviolet (UV) radiation has traditionally been the primary focus of sun protection, visible light (VL), high-energy visible (HEV) light, infrared (IR) radiation, and even heat have … 
ODAC Conference Co-Chair Susan Weinkle, MD, FAAD, is a scientist at heart, which means she’s frequently conducting aesthetic experiments on herself. In this Next Steps in Derm video interview, conducted in partnership with the ODAC Dermatology Conference, Dr. Weinkle shares some of the lessons she’s learned in 25 years of aesthetic self-treatment. For Dr. Weinkle, it’s meant admitting her se …